A considerable literature is growing concerning the subject of the review article by Rosenthal and Gavras published recently in the journal. 1 In this excellent review the authors show that cancer cells of various tissues express components of the renin-angiotensin system and that inhibition of the same system can lead to a decrease in the incidence of cancer in the clinical setting. This review is very comprehensive and covers a good deal of the field. However, I would like to provide an alternative, and perhaps more mechanistic, view of angiotensin (AngII) and its relation to cancer. The exact mechanism(s) of the interaction between AngII and cancer is unknown and could occur during the initiation, the development and/or maintenance of either pathology.
Nevertheless, production of the AngII is well understood; its release into the vascular system is in response to a decrease in blood volume, hypovolaemia. A reduction in blood flow through the kidney juxtaglomerular apparatus releases the enzyme renin into the blood, which cleaves the precursor, angiotensinogen, into angiotensin I. Subsequently, the action of lung angiotensin-converting enzyme leads to the formation of AngII. The principal actions of AngII are vasoconstriction, to increase plasma levels of aldosterone (re-absorption of sodium in the kidneys) and to initiate drinking behaviour. Under ideal physiological conditions these actions support cardiovascular regulation, which in reality means maintaining tissue perfusion (supply to the cells of nutriments), and quickly returns blood volume to normal levels. This, in turn, would decrease the release of renin and thus decrease AngII.
This would imply that hypovolaemia-induced production of AngII could be responsible for an increased risk of cancer, or that hypovolaemia itself could be a risk factor for cancer. 2 It has been suggested previously that the presence of AngII is associated with cellular metabolic dysfunction 3 and that hypovolaemia produces mild hypoxia that could be also associated with metabolic dysfunction. 4 Furthermore, inhibition of the renin-angiotensin system, at least in rats and mice, increases cell metabolism through increased stimulation of drinking. 5 This increased drinking would increase blood volume that would increase cardiac perfusion leading to the production and release of cardiac atrial peptides 2 shown to have an inhibitory action on cancer cells. 6, 7 These results could suggest that increased drinking in response to angiotensin blockade, which would increase plasma volume, could be the mechanism that leads to a decrease in malignancies. In humans, there appears to be less of a drinking response to AngII blockade, 8 which could be part of the explanation as to why not all clinical trials find the same results on cancer with AngII blockade.
In conclusion, encouraging increased drinking to improve blood volume may be a relatively inexpensive way of decreasing plasma levels of the reninangiotensin system and increasing blood oxygenation, and thus reducing the risk of bladder and other cancers. 9 However, the physiological regulation of body fluids is not simple and age-related changes in the cardiovascular system may potentially impair the benefits in older people. Increased fluid consumption in children, adolescents and young adults could be a preventive measure against hypertension and cancer.
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